Fractyl Health, Inc. (Nasdaq: GUTS), a leading metabolic therapeutics company, has announced its intention to conduct a public offering of its common stock and pre-funded warrants. The offering will include common warrants to purchase additional shares and is subject to market and other conditions. Ladenburg Thalmann & Co. Inc. is serving as the sole book-running manager for the offering. The company plans to use the proceeds to support its Revita and Rejuva pipeline programs, as well as for general corporate purposes. The offering's terms will be detailed in a final prospectus supplement to be filed with the SEC.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.